• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新编程功能失调的 CD8 T 细胞对检查点阻断的反应性。

Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells.

机构信息

Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN 55455.

Center for Immunology, University of Minnesota, Minneapolis, MN 55455.

出版信息

Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2640-2645. doi: 10.1073/pnas.1810326116. Epub 2019 Jan 24.

DOI:10.1073/pnas.1810326116
PMID:30679280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6377494/
Abstract

Established T cell dysfunction is a barrier to antitumor responses, and checkpoint blockade presumably reverses this. Many patients fail to respond to treatment and/or develop autoimmune adverse events. The underlying reason for T cell responsiveness remains elusive. Here, we show that susceptibility to checkpoint blockade is dependent on the activation status of T cells. Newly activated self-specific CD8 T cells respond to checkpoint blockade and cause autoimmunity, which is mitigated by inhibiting the mechanistic target of rapamycin. However, once tolerance is established, self-specific CD8 T cells display a gene signature comparable to tumor-specific CD8 T cells in a fixed state of dysfunction. Tolerant self-specific CD8 T cells do not respond to single or combinatorial dosing of anti-CTLA4, anti-PD-L1, anti-PD-1, anti-LAG-3, and/or anti-TIM-3. Despite this, T cell responsiveness can be induced by vaccination with cognate antigen, which alters the previously fixed transcriptional signature and increases antigen-sensing machinery. Antigenic reeducation of tolerant T cells synergizes with checkpoint blockade to generate functional CD8 T cells, which eliminate tumors without concomitant autoimmunity and are transcriptionally distinct from classic effector T cells. These data demonstrate that responses to checkpoint blockade are dependent on the activation state of a T cell and show that checkpoint blockade-insensitive CD8 T cells can be induced to respond to checkpoint blockade with robust antigenic stimulation to participate in tumor control.

摘要

已建立的 T 细胞功能障碍是抗肿瘤反应的障碍,而检查点阻断剂大概可以逆转这种障碍。许多患者对治疗无反应和/或出现自身免疫不良反应。T 细胞反应性的根本原因仍难以捉摸。在这里,我们表明,检查点阻断剂的敏感性取决于 T 细胞的激活状态。新激活的自身特异性 CD8 T 细胞对检查点阻断剂有反应并引起自身免疫,而雷帕霉素的作用机制靶点可以减轻这种反应。然而,一旦建立了耐受,自身特异性 CD8 T 细胞就会表现出与处于固定功能障碍状态的肿瘤特异性 CD8 T 细胞相当的基因特征。耐受的自身特异性 CD8 T 细胞对单剂量或联合使用抗 CTLA4、抗 PD-L1、抗 PD-1、抗 LAG-3 和/或抗 TIM-3 没有反应。尽管如此,用同源抗原进行疫苗接种可以诱导 T 细胞反应性,这会改变之前固定的转录特征,并增加抗原感应机制。耐受 T 细胞的抗原重新教育与检查点阻断协同作用,产生功能性 CD8 T 细胞,这些细胞在没有伴随自身免疫的情况下消除肿瘤,并且在转录上与经典效应 T 细胞不同。这些数据表明,对检查点阻断剂的反应取决于 T 细胞的激活状态,并表明可以通过强烈的抗原刺激诱导对检查点阻断剂无反应的 CD8 T 细胞对检查点阻断剂产生反应,以参与肿瘤控制。

相似文献

1
Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells.重新编程功能失调的 CD8 T 细胞对检查点阻断的反应性。
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2640-2645. doi: 10.1073/pnas.1810326116. Epub 2019 Jan 24.
2
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.舒尼替尼与 PD-L1 阻断联合增强 TLR7/8 激动剂纳米疫苗的抗癌疗效。
Mol Pharm. 2019 Mar 4;16(3):1200-1210. doi: 10.1021/acs.molpharmaceut.8b01165. Epub 2019 Jan 25.
3
Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.顺铂增强抗肿瘤T细胞反应,与程序性死亡受体-配体1(PD-L1)阻断联合使用时可产生强效治疗效果。
Anticancer Res. 2019 Apr;39(4):1749-1760. doi: 10.21873/anticanres.13281.
4
PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii.PD-L1、TIM-3 和 CTLA-4 阻断未能促进对强毒弓形虫株二次感染的抗性。
Infect Immun. 2018 Aug 22;86(9). doi: 10.1128/IAI.00459-18. Print 2018 Sep.
5
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.放疗与疫苗接种相结合可克服免疫检查点阻断抗性。
Oncotarget. 2016 Jul 12;7(28):43039-43051. doi: 10.18632/oncotarget.9915.
6
MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.miR155 通过 PD-1/PD-L1 介导的淋巴瘤细胞与 CD8+T 细胞相互作用使 B 细胞淋巴瘤细胞对抗 PD-L1 抗体敏感。
Mol Cancer. 2019 Mar 30;18(1):54. doi: 10.1186/s12943-019-0977-3.
7
Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8 T Cells.肿瘤浸润髓系细胞表达的共抑制分子 B7 超家族成员 1 诱导抗肿瘤 CD8 T 细胞功能障碍。
Immunity. 2018 Apr 17;48(4):773-786.e5. doi: 10.1016/j.immuni.2018.03.018. Epub 2018 Apr 3.
8
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.LAG-3在小鼠自身耐受和肿瘤耐受系统中调节CD8+ T细胞的积累及效应功能。
J Clin Invest. 2007 Nov;117(11):3383-92. doi: 10.1172/JCI31184.
9
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.放疗和双重检查点阻断激活癌症中的非冗余免疫机制。
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
10
Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.纳米级还原氧化石墨烯介导的光热治疗联合 IDO 抑制和 PD-L1 阻断协同促进抗肿瘤免疫。
ACS Appl Mater Interfaces. 2019 Jan 16;11(2):1876-1885. doi: 10.1021/acsami.8b18751. Epub 2019 Jan 7.

引用本文的文献

1
The diversity of CD8 T cell dysfunction in cancer and viral infection.癌症和病毒感染中CD8 T细胞功能障碍的多样性。
Nat Rev Immunol. 2025 Apr 11. doi: 10.1038/s41577-025-01161-6.
2
Tissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis.组织驻留记忆 T 细胞破坏对肾脏自身抗原的耐受性,并协调免疫介导的肾炎。
Cell Mol Immunol. 2024 Sep;21(9):1066-1081. doi: 10.1038/s41423-024-01197-z. Epub 2024 Jul 3.
3
The CD8 T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects.CD8 T 细胞耐受检查点触发由蛋白质翻译缺陷定义的独特分化状态。
Immunity. 2024 Jun 11;57(6):1324-1344.e8. doi: 10.1016/j.immuni.2024.04.026. Epub 2024 May 21.
4
PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens.PD-1 维持 CD8 T 细胞对皮肤新生抗原的耐受。
Nature. 2023 Jul;619(7968):151-159. doi: 10.1038/s41586-023-06217-y. Epub 2023 Jun 21.
5
Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided "immune-hot" colorectal cancers.激活的组织驻留记忆 T 细胞(CD8+CD103+CD39+)可特异性预测左侧“免疫热”结直肠癌的生存。
Front Immunol. 2023 May 11;14:1057292. doi: 10.3389/fimmu.2023.1057292. eCollection 2023.
6
Reprogramming the tumor microenvironment leverages CD8 T cell responses to a shared tumor/self antigen in ovarian cancer.重编程肿瘤微环境可利用CD8 T细胞对卵巢癌中共享的肿瘤/自身抗原的反应。
Mol Ther Oncolytics. 2023 Feb 9;28:230-248. doi: 10.1016/j.omto.2023.02.002. eCollection 2023 Mar 16.
7
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.树突状细胞表达 CD5 指导 T 细胞免疫并维持免疫治疗反应。
Science. 2023 Feb 17;379(6633):eabg2752. doi: 10.1126/science.abg2752.
8
Assessment of the prognostic value of in clear cell renal cell carcinoma: a bioinformatics analysis.评估[具体内容]在透明细胞肾细胞癌中的预后价值:一项生物信息学分析。 (你原文中“of”后面缺少具体内容)
Transl Androl Urol. 2022 Apr;11(4):509-518. doi: 10.21037/tau-22-161.
9
Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.TLR3/9 激动剂与 PD-1 阻断在逆转电穿孔消融肿瘤免疫耐受微环境中的独特作用及协同效应。
Cell Mol Immunol. 2021 Dec;18(12):2632-2647. doi: 10.1038/s41423-021-00796-4. Epub 2021 Nov 15.
10
Strength and Numbers: The Role of Affinity and Avidity in the 'Quality' of T Cell Tolerance.强度与数量:亲合力和亲和力在 T 细胞耐受的“质量”中的作用。
Cells. 2021 Jun 17;10(6):1530. doi: 10.3390/cells10061530.

本文引用的文献

1
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
2
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.联合免疫检查点阻断(抗 PD-1/抗 CTLA-4):药物不良反应的评估和管理。
Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18.
3
Chromatin states define tumour-specific T cell dysfunction and reprogramming.染色质状态决定肿瘤特异性T细胞功能障碍和重编程。
Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.
4
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.通过靶向PD-1疗法挽救耗竭的CD8 T细胞是依赖CD28的。
Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
5
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
6
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.肿瘤特异性T细胞功能障碍是一种在肿瘤发生早期启动的动态抗原驱动的分化程序。
Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.
7
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.纳武利尤单抗单药治疗及纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌(CheckMate 032):一项多中心、开放标签、Ⅰ/Ⅱ期试验。
Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.
8
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.免疫检查点阻断相关的免疫相关不良事件:一项全面综述。
Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5.
9
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
10
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.